Tempest Therapeutics, Inc.
TPST
$0.91
-$0.08-7.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.65% | -2.56% | -20.52% | -24.06% | -20.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.04% | -60.04% | -44.38% | -6.75% | 26.87% |
| Operating Income | 54.04% | 60.04% | 44.38% | 6.75% | -26.87% |
| Income Before Tax | 6.10% | 3.80% | 37.24% | -1.51% | -35.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.10% | 3.80% | 37.24% | -1.51% | -35.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.10% | 3.80% | 37.24% | -1.51% | -35.75% |
| EBIT | 54.04% | 60.04% | 44.38% | 6.75% | -26.87% |
| EBITDA | 54.34% | 60.28% | 44.50% | 6.33% | -27.66% |
| EPS Basic | 69.93% | 66.19% | 65.53% | 49.15% | 30.19% |
| Normalized Basic EPS | 82.54% | 81.81% | 69.77% | 53.27% | 34.12% |
| EPS Diluted | 69.93% | 66.19% | 65.53% | 49.15% | 30.19% |
| Normalized Diluted EPS | 82.54% | 81.81% | 69.77% | 53.27% | 34.12% |
| Average Basic Shares Outstanding | 186.79% | 133.57% | 93.26% | 114.09% | 105.29% |
| Average Diluted Shares Outstanding | 186.79% | 133.57% | 93.26% | 114.09% | 105.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |